Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab.
OBJECTIVE
To report treatment results with infliximab in 2 pediatric Vogt-Koyanagi-Harada syndrome (VKH) patients.


METHODS
Interventional case series.


METHODS
Medical records of 2 patients were reviewed.


RESULTS
In 1 case with bilateral complete serous detachments, there was improvement but persistent fluid after 2 months of high-dose prednisone, methotrexate, and infliximab therapy. Infliximab was discontinued, and cyclophosphamide monthly intravenous injections were initiated with resolution of all subretinal fluid within 3 weeks. The second patient had mild subretinal fluid around the right optic nerve head tracking into the macula. Treatment with prednisone, methotrexate, and infliximab was initiated, with resolution of the subretinal fluid. Prednisone was tapered off within 4 months, and the inflammation remains controlled.


CONCLUSIONS
Infliximab as adjunctive therapy in pediatric VKH showed a benefit in reducing systemic corticosteroid exposure in 1 patient, but incomplete timely resolution of inflammation in another patient.
Khalifa
Yousuf M
YM
F. I. Proctor Foundation, University of California at San Francisco, San Francisco, California, USA.
Bailony
M Rami
MR
Acharya
Nisha R
NR
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D000069285:Infliximab; D007275:Injections, Intravenous; D041623:Tomography, Optical Coherence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014607:Uveomeningoencephalitic Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D014792:Visual Acuity
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab